Single Institution Experience with G-CSF Mobilized T-Cell Replete Haploidentical Hematopoietic Cell Transplantation
The use of T-cell replete grafts from MHC-haploidentical donors, with post-transplant cyclophosphamide (PTCy) to deplete allo-reactive T cells as acute graft versus host disease (aGvHD) prophylaxis, is efficacious in patients without a matched sibling or timely access to a matched unrelated donor. Traditionally, bone marrow grafts are used to help reduce rates of aGvHD; however, using peripheral blood stem cells (PBSC) grafts in other settings is easier and associated with faster engraftment and decreased relapse rates.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Eric Huselton, Mike Slade, Rizwan Romee Source Type: research
More News: Acute Leukemia | Hematology | Leukemia | Lymphoma | Myeloma | Stem Cell Therapy | Stem Cells | Transplants